Threonyl-MDP

A number of derivatives were synthesized in the hope of identifying a modified form that retained its adjuvanticity but displayed lesser toxicity. Some such derivatives, most notably threonyl-MDP, muramyl tripeptide and murabutide, display some clinical promise in this regard. 

Threonyl-MDP, for example, has been included in the formulation known as Syntax adjuvant formulation-1 (SAF-1). Animal studies suggest that this adjuvant is non-toxic and elicits a good B and T cell response. 

---